NASDAQ: SABS
Sab Biotherapeutics Inc Stock Ownership - Who owns Sab Biotherapeutics?

Insider buying vs selling

Have Sab Biotherapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Andrew MoinDirector2025-09-291,740,000$1.75
$3.05MBuy
Sessa Capital Master LPDirector2025-09-291,740,000$1.75
$3.05MBuy

1 of 1

SABS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SABS insiders and whales buy or sell their stock.

SABS Shareholders

What type of owners hold Sab Biotherapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Vivo Capital LLC22.41%11,420,000$39.63MInstitution
Christine E. Hamilton22.06%11,237,694$38.99MInsider
Edward D. Hamilton19.67%10,023,848$34.78MInsider
Andrew Moin13.31%6,783,028$23.54MInsider
Ilan Katz11.97%6,097,150$21.16MInsider
Eddie Joe Sullivan10.27%5,232,304$18.16MInsider
Commodore Capital LP8.64%4,401,500$15.27MInstitution
Ra Capital Management LP8.64%4,401,500$15.27MInstitution
Samuel J. Reich7.49%3,814,524$13.24MInsider
Big Cypress Holdings LLC5.98%3,047,825$10.58MInsider

1 of 3

SABS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SABS41.21%58.79%Net Buying
FATE51.21%48.79%Net Selling
DTIL35.28%64.72%Net SellingNet Selling
CRBU38.43%8.91%Net SellingNet Selling
ADAG5.22%1.43%

Sab Biotherapeutics Stock Ownership FAQ

Who owns Sab Biotherapeutics?

Sab Biotherapeutics (NASDAQ: SABS) is owned by 71.33% institutional shareholders, 101.77% Sab Biotherapeutics insiders, and 0.00% retail investors. Christine E. Hamilton is the largest individual Sab Biotherapeutics shareholder, owning 11.24M shares representing 22.06% of the company. Christine E. Hamilton's Sab Biotherapeutics shares are currently valued at $38.99M.

If you're new to stock investing, here's how to buy Sab Biotherapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.